Alzheimer’s disease needs a lot more research before a cure is found. And while a lot is being done already, there is still scope for more. Alzheimer’s research needs money, especially if a breakthrough in treating the disease is to be found.
As per Democratic Senator Ed. Markey, a research breakthrough will only happen with more money. Best scientists and best researchers, to find clues, do experiments, work on formulas, and look at WHY Alzheimer’s happens and how it can be prevented, can be pulled in by money. Even today, there is no proper explanation on the cause of the disease.
Alzheimer’s is a terrible disease. It affects the brain, leading to confusion first, and then total memory loss. The disease means a person can be physically healthy but have no idea who they are, who their family is or where they are. It is terrible for the person, terrible for the family, and up to this point, incurable.
“To find a research breakthrough in my opinion just requires pouring more and more money at it so you draw smarter people in greater numbers into try to find the clues,” Markey said at an event.
New treatments are constantly being researched by the Food and Drug Administration (FDA). But even as to accelerate the process of Alzheimer’s research, monetary resources are required in order to yield results. The FDA has been doing research from long time. However, now the organization has to work on limited budgets.
“There’s good work that’s going on with the FDA, there’s more work that needs to be done, [to] get as lean as possible so that we can accelerate research,”Sen. Thom Tillis (R-N.C.) said.
Patients of Alzheimer’s are not alone in their traumatic journey; their family suffers too. But Medical aids and Medicare are stretched to the point of not coping.
The root cause of the disease needs to be identified, so that it could be prevented and cured.
There are ongoing issues between the medical worlds, pharmaceutical worlds, and insurances. Some pharmaceutical companies have terrible reputations for ‘being lean’ with research. Sometimes, it is in the interest of pharmaceutical companies not to find a cure. But not all pharmaceuticals are like this, and should not be tarnished with the same price.
“When lawmakers treat all biotech and pharmaceutical companies the way that they do bad actors, you will have a chilling effect on risk taking and innovation,” Tillis said. “Right now it is very, very popular to cast everybody in biotech and Pharma in the same light as let’s say Turing Pharmaceuticals. That is very dangerous.”